Craft

Advanced
Hemostemix

Hemostemix

Stock Price

$0.1

2024-10-29

Market Capitalization

$16.7 M

2024-10-29

Hemostemix Summary

Company Summary

Overview
Hemostemix is a biotechnology company focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. ACP-01, its clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia.
Type
Public
Status
Active
Founded
2006
HQ
Calgary, CA | view all locations
Website
http://hemostemix.com/
Cybersecurity rating
Sectors

Table of Contents

Key People

  • Ronnie Hershman, Director

    • Peter Lacey, Chairman of the Board

      • Thomas A. Smeenk, President & CEO, Co-Founder and Director

        • Loran Swanberg, Director

          LocationsView all

          1 location detected

          • Calgary, AB HQ

            Canada

            Suite 1150, 707 – 7th Avenue SW

          Hemostemix Financials

          Summary Financials

          Gross profit (FY, 2025)
          $C1.6M
          Net income (FY, 2025)
          ($C4.7M)
          Cash (FY, 2025)
          $C682.0K
          EBIT (FY, 2025)
          ($C4.1M)
          Enterprise value
          $19.6M

          Competitors and Similar Companies

          Compare competitors

          Footer menu

          Product

          Solutions

          Resources

          Company

          © Craft.co 2026
          Share price data provided by IEX